Mechanistic characterization of a new master regulator of cardiac virus infections

心脏病毒感染新主调节因子的机制表征

基本信息

  • 批准号:
    10045127
  • 负责人:
  • 金额:
    $ 58.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-08 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Project Summary Cardiac viral infection is a common cause of heart failure for which therapeutics are lacking. Viruses primarily damage the heart by directly lysing host cells and causing widespread necrosis. The heart responds to infection by recruiting inflammatory cells to fight and prevent the spread of the virus. Inflammation is essential for a successful antiviral response, but excessive inflammation can cause a net harm to the myocardium during infection. The heart must carefully tune inflammation to prevent viral proliferation while avoiding the harm caused by excessive inflammation. Understanding the factors involved in tuning the heart's inflammatory response will be necessary to develop therapeutics for cardiac viral infection. We discovered that a protein called BEX1 (brain expressed X-linked 1) serves a pro-inflammatory role in the heart during sterile injury. We have also found that BEX1 acts in cardiomyocytes as part of a ribonucleoprotein complex regulating the level of pro-inflammatory mRNAs. Nevertheless, the direct mechanism by which BEX1 regulates cardiac inflammation has not been elucidated, and it is not known if BEX1 regulates the heart's response to virus infections. In this proposal we seek to understand BEX1's role in the response of the heart to viruses with the following aims: 1) To determine the effect of BEX1 on cardiotropic viral infection in vivo; 2) To determine the contribution of BEX1 to antiviral gene programs in the heart; and 3) To elucidate the mechanism by which BEX1 regulates antiviral responses. Preliminary data have led us to the hypothesis that BEX1 plays an antiviral role by regulating a protein called EPRS (glutamyl-prolyl-tRNA synthetase). Evaluating this hypothesis and elucidating the role of BEX1 in immunity and inflammation will be necessary to gain a better understanding of viral infection and inflammatory diseases, and could lead to the discovery of valuable therapeutic targets.
项目摘要 心脏病毒感染是缺乏治疗剂的心力衰竭的常见原因。病毒主要是 通过直接裂解宿主细胞并导致广泛坏死来损害心脏。心脏回应 通过招募炎症细胞来抗击并防止病毒的传播。炎症是必不可少的 对于成功的抗病毒反应,但过度炎症会对心肌造成净伤害 感染。心脏必须仔细调节炎症,以防止病毒增殖,同时避免伤害 由过度炎症引起。了解调整心脏炎症的因素 为了开发心脏病毒感染的治疗剂是必要的。我们发现一种蛋白质 在无菌损伤过程中,称为BEX1(脑表示X连锁1)在心脏中发挥了促炎作用。我们 还发现BEX1在心肌细胞中起作用,作为调节水平的核糖核蛋白复合物的一部分 促炎性mRNA。然而,BEX1调节心脏的直接机制 炎症尚未阐明,尚不清楚BEX1是否调节心脏对病毒的反应 感染。在此提案中,我们试图了解Bex1在心脏对病毒反应中的作用 以下目的:1)确定BEX1对体内心脏病毒感染的影响; 2)确定 BEX1对心脏中抗病毒基因程序的贡献; 3)阐明了该机制 BEX1调节抗病毒反应。初步数据使我们提出了BEX1抗病毒的假设 通过调节称为EPRS的蛋白质(谷氨酸 - 丙基-TRNA合成酶)的作用。评估这一假设和 阐明BEX1在免疫和炎症中的作用以更好地了解 病毒感染和炎症性疾病,可能导致发现有价值的治疗靶标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Federica Accorner...的其他基金

METTL3 in regulation of the aging process
METTL3 调节衰老过程
  • 批准号:
    10748833
    10748833
  • 财政年份:
    2023
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
METTL3 in regulation of the aging process
METTL3 调节衰老过程
  • 批准号:
    10936572
    10936572
  • 财政年份:
    2023
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
Mechanistic characterization of a new master regulator of cardiac virus infections
心脏病毒感染新主调节因子的机制表征
  • 批准号:
    10255819
    10255819
  • 财政年份:
    2020
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
Mechanistic characterization of a new master regulator of cardiac virus infections
心脏病毒感染新主调节因子的机制表征
  • 批准号:
    10455582
    10455582
  • 财政年份:
    2020
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
Mechanistic characterization of a new master regulator of cardiac virus infections
心脏病毒感染新主调节因子的机制表征
  • 批准号:
    10672435
    10672435
  • 财政年份:
    2020
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
Post-transcriptional regulation of cardiac hypertrophy
心脏肥大的转录后调控
  • 批准号:
    9902509
    9902509
  • 财政年份:
    2017
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
Post-transcriptional regulation of cardiac hypertrophy
心脏肥大的转录后调控
  • 批准号:
    10655127
    10655127
  • 财政年份:
    2017
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
Post-transcriptional regulation of cardiac hypertrophy
心脏肥大的转录后调控
  • 批准号:
    10062708
    10062708
  • 财政年份:
    2017
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
Post-transcriptional regulation of cardiac hypertrophy
心脏肥大的转录后调控
  • 批准号:
    10892484
    10892484
  • 财政年份:
    2017
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
BEX1 and the control of protein translation in cardiac hypertrophy
BEX1 和心脏肥大中蛋白质翻译的控制
  • 批准号:
    8787792
    8787792
  • 财政年份:
    2013
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:

相似海外基金

Activity-Dependent Regulation of CaMKII and Synaptic Plasticity
CaMKII 和突触可塑性的活动依赖性调节
  • 批准号:
    10817516
    10817516
  • 财政年份:
    2023
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
Emerging mechanisms of viral gene regulation from battles between host and SARS-CoV-2
宿主与 SARS-CoV-2 之间的战斗中病毒基因调控的新机制
  • 批准号:
    10725416
    10725416
  • 财政年份:
    2023
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
Glia Exclusive Gene Therapy
胶质细胞独家基因疗法
  • 批准号:
    10739502
    10739502
  • 财政年份:
    2023
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
Genetic and pharmacologic elimination of myotonia from myotonic dystrophy type 1
通过遗传和药物消除 1 型强直性肌营养不良引起的肌强直
  • 批准号:
    10750357
    10750357
  • 财政年份:
    2023
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别:
Development of Utrophin Site Blocking Oligos (SBOs) to Treat Duchenne Muscular Dystrophy (DMD)
开发 Utropin 位点封闭寡核苷酸 (SBO) 来治疗杜氏肌营养不良症 (DMD)
  • 批准号:
    10678195
    10678195
  • 财政年份:
    2023
  • 资助金额:
    $ 58.14万
    $ 58.14万
  • 项目类别: